Q BioMed Inc. (OTCMKTS:QBIO – Get Rating) was the recipient of a significant growth in short interest in the month of December. As of December 30th, there was short interest totalling 189,900 shares, a growth of 21.2% from the December 15th total of 156,700 shares. Based on an average daily trading volume, of 1,488,100 shares, the short-interest ratio is presently 0.1 days.

Q BioMed Price Performance

Shares of QBIO stock opened at $0.01 on Friday. Q BioMed has a 12-month low of $0.01 and a 12-month high of $0.49. The company has a market capitalization of $909,090.00, a PE ratio of -0.04 and a beta of 2.44. The firm has a 50 day moving average price of $0.01 and a two-hundred day moving average price of $0.03.

Q BioMed (OTCMKTS:QBIO – Get Rating) last released its earnings results on Thursday, November 3rd. The company reported ($0.03) EPS for the quarter. The business had revenue of $0.03 million for the quarter.

Q BioMed Company Profile

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain.

Read More

• Get a free copy of the StockNews.com research report on Q BioMed (QBIO)
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point
• High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.